TransMedics Group (NASDAQ:TMDX) CFO Gerardo Hernandez Sells 7,236 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the sale, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at $2,162,367.69. The trade was a 33.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Gerardo Hernandez also recently made the following trade(s):

• On Monday, March 2nd, Gerardo Hernandez sold 375 shares of TransMedics Group stock. The stock was sold at an average price of $139.12, for a total value of $52,170.00.
• On Thursday, December 4th, Gerardo Hernandez sold 920 shares of TransMedics Group stock. The stock was sold at an average price of $139.62, for a total value of $128,450.40.

TransMedics Group Stock Performance

TMDX traded down $0.34 during trading on Wednesday, hitting $147.66. 701,764 shares of the stock were exchanged, compared to its average volume of 830,019. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a 1-year low of $62.07 and a 1-year high of $156.00. The stock has a fifty day moving average price of $134.97 and a two-hundred day moving average price of $126.78. The firm has a market capitalization of $5.06 billion, a P/E ratio of 30.13 and a beta of 1.98.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in TMDX. Vanguard Group Inc. boosted its holdings in TransMedics Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after purchasing an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after buying an additional 113,817 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after buying an additional 322,353 shares during the period. Geode Capital Management LLC boosted its stake in shares of TransMedics Group by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after buying an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after acquiring an additional 223,409 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMDX. Oppenheimer upped their price target on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Needham & Company LLC increased their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Piper Sandler raised their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Morgan Stanley boosted their price target on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.